EP Patent

EP3845215B1 — Oral solutions comprising lisdexamfetamine salts

Assigned to Adalvo Ltd · Expires 2022-07-27 · 4y expired

What this patent protects

Patent listed against lisdexamfetamine-dimesylate.

Drugs covered by this patent

Patent Metadata

Patent number
EP3845215B1
Jurisdiction
EP
Classification
—
Expires
2022-07-27
Drug substance claim
No
Drug product claim
No
Assignee
Adalvo Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.